AKT1 and acute lymphoblastic leukemia: To functionally validate the putative contribution of each of these mutations to steroid resistance in T-ALL, Meijerink and colleagues generated a panel of isogenic tumor lines with inducible expression of IL7R–RAS–MAPK–AKT pathway mutations.